Reference

Quality survey of inositol niacinate

Quality survey of inositol niacinate. Fan, Jifen; Li, Lijian (Tianjin Inst. Drug Control, Tianjin, Peop. Rep. China). Yaowu Fenxi Zazhi, 4(2), 112-13 (Chinese) 1984. CODEN: YFZADL. ISSN: 0254-1793. DOCUMENT TYPE: Journal CA Section: 63 (Pharmaceuticals) Inositol niacinate (I) [6556-11-2] prepd. by the DMF [68-12-2] or the DMSO [67-68-5] and the acid-base methods was compared. The m.p. of I prepd. by the DMF and DMSO methods was 257-61° and that by the acid-base method was 255-60°. TLC indicated that I prepd. by the acid-base method contained 2 impurities, but no impurity was obsd. in I prepd. by the 2 other methods (4 treatments with DMF or DMSO). IR spectra indicated that I prepd. by different methods showed similar patterns. Impurities were due to incomplete esterification. NaOH hydrolysis products of purified I were identical to impurities in crude I as detd. by TLC.

Combination of monotherapy of hyperlipoproteinemia type IIb, IV, and V with clofibrate and myo-inositol nicotinate or clofibric acid

Combination of monotherapy of hyperlipoproteinemia type IIb, IV, and V with clofibrate and myo-inositol nicotinate or clofibric acid. Schwartzkopff, W.; Zschiedrich, M. (Klin. Charlottenburg, Freie Univ. Berlin, Berlin, Ger.). Med. Klin. (Munich), 73(7), 231-9 (German) 1978. CODEN: MEKLA7. ISSN: 0025-8458. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacodynamics) In patients with type IIb, IV, or V hyperlipoproteinemias, 30-wk oral administration of 1.5 g clofibrate (I) [637-07-0]/day plus 1.2 g myo-inositol nicotinate (II) [6556-11-2]/day decreased the triglycerides in the serum high-, low-, and very-low-d. lipoproteins, esp. in the latter. However, the combination I-II therapy did not prevent the conversion of phenotype IV to IIa or IIb which also occurred during monotherapy with either I or clofibric acid [882-09-7]. Approx. 25% of the patients on the I-II combination showed an increase in b-(low-d.) lipoprotein-bound cholesterol [57-88-5] to the pathol. range of >210 mg/dL. Combination I-II therapy gave no real improvement over monotherapy with I or clofibric acid with respect to lowering serum triglycerides and cholesterol. A combination therapy with I and nicotinic acid or nicotinate esters would presumably be useful only if the nicotinate were given in such high doses as to cause side effects.